Churg-Strauss vasculitis in patient who received montelukast

Vojislav Ćupurdija; Ivan Čekerevac; Marina Petrović; Gordana Kostić; Romana Suša; Zorica Lazić

doi:10.2298/VSP160828351C

Vojislav Ćupurdija Fakultet medicinskih nauka, Univerzitet u Kragujevcu; Klinika za pulmologiju, Klinički centar Kragujevac
Ivan Čekerevac Fakultet medicinskih nauka, Univerzitet u Kragujevcu; Klinika za pulmologiju, Klinički centar Kragujevac
Marina Petrović Fakultet medicinskih nauka, Univerzitet u Kragujevcu; Klinika za pulmologiju, Klinički centar Kragujevac
Gordana Kostić Fakultet medicinskih nauka, Univerzitet u Kragujevcu; Klinika za pedijatriju, Klinički centar Kragujevac
Romana Suša Klinika za pulmologiju, Klinički centar Kragujevac
Zorica Lazić Fakultet medicinskih nauka, Univerzitet u Kragujevcu; Klinika za pulmologiju, Klinički centar Kragujevac

DOI: https://doi.org/10.2298/VSP160828351C

Keywords: churg-strauss syndrome;, leukotriene antagonists;, diagnosis;, drug therapy;, treatment outcome;, asthma.

Abstract

Abstract

Introduction. Montelukast is a selective leukotriene receptor antagonist. One of side effects of this drug class is the Churg- Strauss syndrome (CSS). There is still no reliable evidence whether the expression of this syndrome could be masked by high doses of corticosteroids and become expressed by termination of corticosteroid use, or whether it could be a consequence of leukotriene receptor antagonists use. Case report. Female patient, aged 49 years, was hospitalized with symptoms of fever, dyspnea, cough and increased sputum production with occasional hemoptysis. She was treated for asthma during the previous year. Leukocyte differential formula registered 44% of eosinophils. IgE value was extremely elevated, with value measured to 580 kU/L and eosinophile cation protein value was 15.1 µg/L. Computed tomography of the chest described changes in the form of ground glass located in all lobes of the right lung and in the upper lobe of the left lung. Computed tomography of paranasal sinuses described changes that could resemble to polyposis, chronic sinusitis, and possible granulomatosis. Mononeuritis of peroneal nerve of the right leg was proven by electromyographic examination. Bone marrow biopsy indicated hypercellularity with domination of eosinophilic granulocytes (30%). Five out of six criteria were noted in patient’s clinical presentation, after which the diagnosis of CSS was set. The patient began treatment with high doses of corticosteroids while montelukast was discontinued which resulted in disease remission. Conclusion. Although there is no evidence that leukotriene modifiers cause the CSS in all patients with asthma, in case of frequent exacerbations with the appearance of pulmonary infiltrates, eosinophilia and paranasal sinus abnormalities make one think of this form of vasculitis.

References

Reference:

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33(8): 1094−100.

Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78(1): 26−37.

Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: A review of case reports in the literature. Pharmacology 2014; 94(1−2): 60−70.

Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, et al. Churg-Strauss syndrome in patients receiv-ing montelukast as treatment for asthma. Chest 2000; 117(3): 708−13.

Uyar M, Elbek O, Bakir K, Kibar Y, Bayram N, Dikensoy Ö. Churg-Strauss syndrome related to montelukast. Tuberk To-raks 2012; 60(1): 56−8.

Black JG, Bonner JR, Boulware D, Andea AA. Montelukast-associated Churg-Strauss vasculitis: another associated report. Ann Allergy Asthma Immunol 2009; 102(4): 351−2.

Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108(2): 175−83.

Villena V, Hidalgo R, Sotelo MT, Martin-Escribano P. Montelukast and Churg-Strauss syndrome. Eur Respir J 2000; 15(3): 626−6.

Solans R, Bosch J, Selva A, Orriols R, Vilardell M. Montelukast and Churg Strauss syndrome. Thorax 2002; 57(2): 183−5.

Keogh KA. Leukotriene receptor antagonists and Churg-Strauss syndrome: Cause, trigger or merely an association? Drug Saf 2007; 30(10): 837−43.

Jamaleddine G, Diab K, Tabbarah Z, Tawil A, Arayssi T. Leuko-triene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002; 31(4): 218−27.

Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal. Drug Saf 1999; 21(4): 241−51.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239−45.